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Viral protein homeostasis depends entirely on the
machinery of the infected cell. Accordingly, viruses
can illuminate the interplay between cellular proteo-
stasis components and their distinct substrates.
Here, we define how the Hsp70 chaperone network
mediates the dengue virus life cycle. Cytosolic
Hsp70 isoforms are required at distinct steps of the
viral cycle, including entry, RNA replication, and
virion biogenesis. Hsp70 function at each step is
specified by nine distinct DNAJ cofactors. Of these,
DnaJB11 relocalizes to virus-induced replication
complexes to promote RNA synthesis, while DnaJB6
associates with capsid protein and facilitates virion
biogenesis. Importantly, an allosteric Hsp70 inhibi-
tor, JG40, potently blocks infection of different
dengue serotypes in human primary blood cells
without eliciting viral resistance or exerting toxicity
to the host cells. JG40 also blocks replication of other
medically-important flaviviruses including yellow fe-
ver, West Nile and Japanese encephalitis viruses.
Thus, targeting host Hsp70 subnetworks provides a
path for broad-spectrum antivirals.
INTRODUCTION
A third of the world population is at risk of infection with the mos-
quito-borne dengue virus (DENV) (Bhatt et al., 2013; Shepard
et al., 2014), with an estimated 390 million infections annually
(Bhatt et al., 2013). Any of four serotypes causes a range of se-
vere diseases; dengue fever (DF) is a debilitating acute flu-like
illness, while dengue hemorrhagic fever (DHF) and dengue shock
syndrome (DSS), with about 500,000 cases annually, are life-
threatening diseases typified by vascular leakage and circulatory
shock (Halstead, 2007)(Bhatt et al., 2013). DENV’s major in vivo
targets in humans are myeloid cells, including dendritic cells
(DCs) and macrophages (Schmid et al., 2014). The dysregulated
overproduction of cytokines and chemokines during DENV1108 Cell 163, 1108–1123, November 19, 2015 ª2015 Elsevier Inc.infection is thought to contribute to the increased vascular
permeability, disruption of the coagulation system and shock
associated with DHF/DSS (Rothman, 2011). Despite its burden
on global health, no specific antivirals or vaccines are licensed
for human use (Lim et al., 2013).
DENV belongs to the genus Flavivirus of the family Flaviviridae,
comprising other clinically relevant arthropod-borne viruses such
as yellow fever virus (YFV), West Nile virus (WNV), Japanese en-
cephalitis virus (JEV) and tick-borneencephalitis virus (TBEV) (Lin-
denbach et al., 2007). Flaviviruses have a capped positive-sense
single-strandedRNAgenomeof11kb that encodesasinglepol-
yprotein,which isco-andpost-translationally cleavedbyhost and
viral proteases into three structural (capsid, prM, andE) and seven
non-structural (NS1, NS2A/B, NS3, NS4A/B, and NS5) proteins
(Apte-Sengupta et al., 2014; Lindenbach et al., 2007). Capsid en-
capsidates the genomic RNA and is then enveloped by mem-
branes containing prM and E to produce progeny virions (Perera
and Kuhn, 2008). The non-structural proteins are involved in viral
replication and modulate the host cell environment by, for
example, remodeling cellularmembranes or inhibiting immune re-
sponses (Rothman, 2011; Rodriguez-Madoz et al., 2010).
Like all RNA viruses, flaviviruses are dependent on the host
cell machinery for replication. With only ten proteins, DENV
completely remodels the cell and generates an ER-derived
membranous web (Junjhon et al., 2014; Welsch et al., 2009),
where viral replication complexes are assembled. DENV proteins
also associate with lipid droplets (LD) (Figure 1A) (Samsa et al.,
2009). The ability of such a small genome to remodel the cell is
linked to the structural and functional complexity of DENV pro-
teins (Perera and Kuhn, 2008). This, in turn, presents a challenge
to viral protein folding and assembly. Indeed, many viruses
depend on host molecular chaperones for folding and proteosta-
sis (Mayer, 2005; Nagy and Pogany, 2012). Chaperones are
reported to facilitate flavivirus replication; ER chaperones asso-
ciate with DENV E (Limjindaporn et al., 2009), and Hsp70 pro-
tects JEV NS3 and NS5 from degradation (Ye et al., 2013).
However, the interplay between chaperone networks and the
viral life cycle remains unclear. The structural complexity and
accumulation to high levels of viral proteins may make viruses
hyper-dependent on chaperones, and vulnerable to their inhibi-
tion (Neckers and Tatu, 2008; Geller et al., 2012).
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Figure 1. Cytosolic Hsp70 Isoforms Are Required for DENV Life Cycle
(A) DENV life cycle highlighting major steps and their subcellular localization. Nu, nucleus; LD, lipid droplet; Mito, mitochondria, ER; endoplasmic reticulum.
(B) Depletion of cytosolic Hsp70 isoforms reduces DENV replication. In vitro transcribed DENV RNA introduced by electroporation; 48 hr post-infection (hpi),
supernatants were harvested and extracellular virus titrated by focus forming assay (FFA). Ctrl: shRNA against luciferase as a control.
(legend continued on next page)
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Pharmacological chaperone inhibitors are emerging as prom-
ising cancer therapies, particularly Hsp90 inhibitors (Neckers
and Tatu, 2008; Trepel et al., 2010). A number of viruses are
also sensitive to Hsp90 inhibitors (Geller et al., 2012), without
evolving drug-resistant viral escape variants (Geller et al.,
2013; Geller et al., 2007). Since drug resistance is a major stum-
bling block in antiviral treatment (De Clercq, 2007), the potential
inability of viruses to become chaperone-independent makes
chaperones attractive antiviral drug targets.
We have a limited understanding of the chaperone network ar-
chitecture and its relationship to the organization of the cell (Hartl
et al., 2011). One hallmark of the evolution of the chaperone ma-
chinery is the progressive diversification of chaperone isoforms
and cofactors (Powers and Balch, 2013). In bacteria there is
oneHsp70chaperoneandoneHsp70cofactor,DnaJ,while in hu-
mans there are 13 Hsp70s and over 45 DNAJ-like proteins (Kam-
pinga andCraig, 2010; Powers andBalch, 2013). This diversifica-
tion may allow more nuanced regulation of chaperone activity in
an increasingly complex proteome. Understanding how chap-
erone systems facilitate a complex phenotype like viral infection
could provide awindow into the functional specialization of chap-
erone isoforms. Here, we address the role of Hsp70 chaperones
and their DnaJ cofactors in theDENV life cycle.We find that cyto-
solicHsp70s, assistedbydistinctly localizedDnaJ’s, are required
at multiple steps of the viral life cycle. Importantly, Hsp70 pro-
vides a susceptible node for antiviral Hsp70 inhibitors, with negli-
gible toxicity and no resistance. Hsp70 inhibitors block the repli-
cation of diverse DENV serotypes and other flaviviruses (WNV,
YFV, TBEV). The multifaceted roles of Hsp70 subnetworks in fla-
vivirus infectionmay provide the basis for broad-spectrum, resis-
tance-free antivirals for a range of human diseases.
RESULTS
Hsp70 Is Required for DENV Infection of Human and
Mosquito Cells
To explore the involvement of Hsp70 in the DENV lifecycle (Fig-
ure 1A), we established six Hsp70 isoform-specific shRNA
knockdown (KD) cell lines (Figure S1A) and confirmed reduction
of mRNA (50%–80%, Figure S1A) and protein (50%–95%, Fig-
ure S1B). While reductions in some Hsp70 isoforms upregulated
others, Hsp90 immunoblot confirmed that a general stress
response was not induced (Figure S1B). Depletion of cytosolic
HSPA1A, 1B and 8, (also called Hsp70-1A, 1B and Hsc70,
respectively) significantly reduced DENV infectious particle pro-
duction (Figure 1B). In contrast, depletion of ER-resident Hsp70
HSPA5 (BiP) or mitochondrial Hsp70 HSPA9 had no effect on
DENV (Figure 1B). KD of all cytosolic isoforms caused similar re-(C) Overexpression of dominant-negative cytosolic Hsp70 but not ER Hsp70 BiP
T229G) of cytosolic (HSPA8) or ER (BiP) Hsp70 were transduced into Huh7 cells.
quantified 36 hpi by FFA.
(D) Hsc70/Hsp70 co-localizes with DENV replication compartments. Huh7 cells i
antibody (green), dsRNA (blue) and NS3 (red), marking viral replication sites. Sca
(E) Hsp70 chaperone and ATPase cycle is regulated by co-chaperone cofactors
binding to Hsp70. JG18, JG40 and MKT077 block binding of Hsp70 to Nucleotid
(F–H) Hsp70 inhibitors suppress DENV propagation in human and mosquito cell
(H) cells infectedwith DENV2 atMOI 0.5 for 1 hr, and inhibitors added for 36 hr (Huh
expressed as means ± SD of three independent experiments each carried out in
1110 Cell 163, 1108–1123, November 19, 2015 ª2015 Elsevier Inc.ductions in viral RNA (vRNA) levels (Figure S1C) but HSPA8 had
the most dramatic effect on virion production (Figure 1B).
Furthermore, overexpression of dominant-negative cytosolic
Hsc70, mutated in the ATPase active site (HSPA8 K71A) (O’Brien
et al., 1996), significantly and dose dependently reduced vRNA
replication and virion production (Figure 1C, S1D). In contrast,
dominant-negative BiP (HSPA5 T229G) had no effect. Immuno-
fluorescence analysis showed that cytosolic Hsp70s, while
ubiquitous, were concentrated in viral replication complexes
containing double-stranded RNA (dsRNA) and NS3 (Figure 1D;
see S1E for uninfected control).
To overcome the confounding effects of functional redun-
dancy between Hsp70 isoforms we employed a chemical
biology approach. Hsp70 is a weak ATPase regulated by several
sets of cellular cofactors (Figure 1E) (Hartl et al., 2011). DnaJ-like
proteins contain a J-domain that binds Hsp70 and promotes
ATP hydrolysis, stabilizing the substrate-Hsp70 complex.
Many DnaJ homologs also have domains that help deliver sub-
strate proteins to Hsp70. Nucleotide exchange factors (NEFs)
promote the release of Hsp70-bound substrates. Chemical
modulators that interfere with these enzymatic activities and pro-
tein-protein interactions have been developed (Assimon et al.,
2013). One class of molecules, exemplified by VER155008, com-
petes with ATP for Hsp70 binding (Williamson et al., 2009), while
MKT077 and its analogs target Hsp70-NEF interactions (Fig-
ure 1E) (Assimon et al., 2013; Li et al., 2015; Li et al., 2013). We
used both VER155008 and MKT077 and two improved
MKT077 analogs, JG18 and JG40 (Figure 1E). Of note,
MKT077 analogs act similarly to the Hsp70 mutant K71A, since
both stabilize Hsp70-substrate interactions by blocking NEF
binding (Wang et al., 2013). The binding site of MKT077 analogs
is known and conserved across eukaryotes and all Hsp70 iso-
forms (Assimon et al., 2013), thus the compounds function in
both natural DENV hosts, humans, and mosquitoes (Figures
1F–1H). Indeed, JG18, JG40, and VER155008 dose dependently
blocked DENV propagation in human (Huh7) cells (Figure 1G),
while MKT077, JG18, and JG40 suppressed DENV in mosquito
(C6/36) cells (Figure 1H). The fact that these chemically distinct
compounds block DENV propagation is strong evidence for a
role for Hsp70 in DENV replication. Furthermore, the structurally
similar but inactive JG18 and JG40 derivatives JG19 and JG28
did not suppress DENV propagation (Figure S1F). Thus, both ge-
netic (Hsc70 K71A) and chemical (JG40, JG18) disruption of
Hsp70-NEF function inhibited DENV replication, demonstrating
the selectivity of the compounds and supporting a role for
Hsp70 in DENV replication.
We next focused on the second-generation, metabolically sta-
ble MKT077 analogs, JG18 and JG40 (Li et al., 2013). A concernreduces DENV propagation. Wild-type (WT) or dominant negatives (K71A or
Transfected cells were infected with DENV2 at MOI 0.5 and extracellular virus
nfected with DENV2 were stained at 48 hpi with a pan cytosolic Hsc70/Hsp70
le bar, 10 mm
and targeted by inhibitors. Hsp70 inhibitors used here: VER15508 blocks ATP
e Exchange Factors (NEF).
s in a dose dependent manner. (F) Experimental design: Huh7 (G) and C6/36
7 cells) or 48 hr (C6/36 cells). Extracellular virus: determined by FFA.All data are
triplicate. *p < 0.01, **p < 0.005.
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Figure 2. Hsp70s Facilitate Multiple Steps in the DENV Viral Life Cycle
(A) Hsp70 inhibition blocks viral entry and post-entry steps. Time course of drug-addition experiment vis-a-vis DENV infection compared JG40 (Hsp70i); entry
inhibitor heparin (HP) and NS5 polymerase inhibitor (20CMA). Huh7 cells infected with DENV2 at MOI 0.5. Intracellular DENV RNA and extracellular viral pro-
duction: measured by qRT-PCR and FFA, respectively.
(B) JG40-treatment suppresses DENV replication post-entry. DENV RNA electroporated into Huh7 cells and inhibitors added 6 hpi. After 48 hr, intracellular vRNA
was quantified by qRT-PCR.
(C) Hsp70 inhibition decreases DENV capsid and NS5 protein levels. Huh7 cells infected with DENV2 at MOI 0.5 for 36 hr. Inhibitors were then added and cells
harvested as indicated. The levels of viral and host proteins during treatment were assessed by immunoblot using IR fluorescence on a Li-Cor Odyssey System
(see Fig.S2F-S2G). (D) Hsp70 functions at different steps in the DENV lifecycle suggesting low chances of viral resistance to the drug.
(legend continued on next page)
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with Hsp70 inhibitors is that they may block essential chaperone
functions, leading to host cell toxicity. However, allosteric inhib-
itors of the Hsp70-NEF complex are surprisingly non-toxic in
normal fibroblasts and animals (Assimon et al., 2013; Li et al.,
2015; Li et al., 2013), likely because they leave other chaperone
functions intact. Consistent with the idea that viral infection cre-
ates a hyper-dependence on distinct chaperone activities
compared to host proteostasis, neither JG18 nor JG40 was toxic
to host cells at concentrations that inhibit viral replication, as
measured by the complementary MTT and LDH release assays
(Figure S1G).
Hsp70 Acts at Multiple Steps in the DENV Infectious
Cycle
The activity of Hsp70 inhibitors on DENV replication was compa-
rable to a previously described NS5 polymerase inhibitor,
20C-methyladenosine (20CMA; Figures S2A–S2E). Hsp70 inhibi-
tors and 20CMA suppressed vRNA synthesis (Figures S2A and
S2B) and viral protein expression (vProtein; Figure S2C) in hu-
man and mosquito cells. To dissect which steps in the viral life
cycle require Hsp70 in human cells, we performed an order-of-
addition experiment using JG40, 20CMA, and the entry inhibitor
heparin (HP). As expected, HP only blocked vRNA replication
and viral production (Figure 2A, series I-IV) when added prior
to or concurrently with DENV infection (Figure 2A, series V). In
contrast, 20CMA was effective only when added concurrently
with or after infection (Figure 2A, series III-V). JG40 inhibits
DENV production and vRNA replication in any of these treatment
regimes, indicating that Hsp70 is required both at entry and for
post-entry steps (Figure 2A, series I-V). To bypass viral entry,
we directly electroporated in vitro transcribed genomic vRNA
into Huh7 cells in the presence of these various compounds.
As expected, HP no longer inhibited viral replication, but both
20CMA and JG40 inhibited vRNA production to a similar extent
(Figure 2B). Thus, Hsp70 is required for both entry and post-entry
steps of the viral life cycle.
A drug-chase experiment in infected cells next examined
whether Hsp70 inhibitors specifically affect individual DENV pro-
teins. Huh7 cells were infected with DENV for 36 hr; then either
20CMA, JG40, or vehicle were added and the level of viral RNA
and proteins examined during a 24 hr time course. Both
20CMA and JG40 blocked vRNA production to a similar degree,
and no new vRNAwas synthesized during the chase (Figure S2A,
4F). Both drugs also decreased the expression of cytosolic and
ER viral proteins (Figure 2C, S2F and S2G; see Experimental Pro-
cedures). All DENV proteins are translated in an equimolar ratio
as a single polyprotein, but their steady-state levels are also
determined by their half-life. For a given protein, the ratio be-
tween 20CMA and JG40 treatment should reveal which proteins
are further destabilized by Hsp70 inhibition, a hallmark of an
Hsp70 substrate. The levels of cytosolic NS3 and membrane-
bound E, prM, NS2B, and NS4B all decreased to a similar extent(E) Serial passaging of DENV in JG40 to test development of drug resistance. A
presence or absence of JG40. Virus produced in each passage served as input
(F) DENV remains JG40-sensitive following serial passage in the presence of
Extracellular virus produced in the presence or absence of JG40 was quantified
All data are expressed as mean ± SD of three independent experiments. *p < 0.0
1112 Cell 163, 1108–1123, November 19, 2015 ª2015 Elsevier Inc.upon 20CMA or JG40 treatment (Figure 2C, S2G). In contrast,
JG40 disproportionately reduced the levels of NS5 and capsid
(Figure 2C, S2G). This is not due to positional effects on transla-
tion, since the capsid is the most N-terminal protein in the poly-
protein andNS5 themost C-terminal. Thus, Hsp70 is required for
folding and/or stabilization of capsid and NS5, suggesting these
proteins are Hsp70 substrates (Figure 2D).
Dengue Virus Cannot Develop Resistance to Small
Molecule Inhibitors of Hsp70
The mutational plasticity of viruses allows them to escape from
most antiviral drugs targeting viral and even host factors
(Dowd et al., 2014; Lauring et al., 2013). The spread of resistant
viruses then renders drugs completely or partially ineffective. To
determine if DENV can escape treatment with Hsp70 inhibitors,
we serially passaged DENV in the presence of 20CMA (Fig-
ure S2D) or 3 mM JG40 (Figure 1G). At each passage, the drug-
sensitivity of the untreated and compound-passaged virus was
tested in the presence of JG40 or 20CMA (Figure 2E, S2H).
Even after ten passages in the presence of JG40, the virus re-
mained as sensitive to JG40 as untreated or parental virus (Fig-
ure 2F) while virus passaged in 20CMA developed significant
resistance against 20CMA by passage 10 (Figure S2H). Similar
results were obtained in at least three independent biological
replicates (data not shown). These results, together with the
low toxicity of JG40 in human cells, suggest Hsp70 inhibitors
could provide an antiviral treatment against DENV replication
that exhibit reduced emergence of drug resistant variants.
Cytosolic Hsp70 Is Required for NS5 Stability and Its
Polymerase Function
To examine whether the observed decrease in NS5 upon Hsp70
inhibition is due to proteasomal degradation, cells infected with
DENV for 36 hr were treated with JG40 for an additional 12 hr
with or without the proteasome inhibitor MG132 (Figure 3A).
Indeed, the JG40-induced reduction in NS5 was abrogated by
proteasome inhibition (Figure 3A). Furthermore, Hsp70 appears
to act directly on NS5 in the absence of other viral proteins, as
transfected HA-NS5 was also degraded upon addition of JG40
in a proteasome-dependent manner (Figure 3B). NS5 also co-
immunoprecipitated with Hsp70 (Figure 3C). Even though
MG132 abrogated the JG40-induced NS5 reduction (Figures
3A and 3B), restoring NS5 levels did not rescue vRNA synthesis
or virus production (Figure 3D). Since MG132 does not block
DENV replication under the conditions of the experiment, it ap-
pears that Hsp70 is not only required for NS5 stability, but also
for the acquisition of its folded, functional state. To test this,
we isolated active crude replication complexes (RCs) from
DENV-infected cells. These RCs produce vRNA in an NS5-
dependent manner (Figure 3E), allowing us to examine the effect
of JG40 on the activity of NS5 that has already folded and
assembled into the large multi-component replication complex.t each passage, Huh7 cells were infected with DENV2 at an MOI of 0.5 in the
in the next passage in the absence (Mock) or presence (JG40) of drug.
JG40. JG40 sensitivity for the indicated virus passages obtained as above.
by FFU assay 36 hpi.
5, **p < 0.01, ***p < 0.005, ****p < 0.001, *****p < 0.0005.
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Figure 3. Hsp70 Required for Polymerase NS5 Biogenesis and Function
(A) Hsp70 inhibition leads to proteasomal degradation of NS5. Huh7 cells were infected with DENV2 at MOI 0.5. At 36 hpi, JG40 was added with or without
proteasome inhibitor MG132 for an additional 12 hr. Immunoblot analysis (left panel) and quantification (right panel) show that JG40-induced NS5 decrease is
rescued by MG132.
(legend continued on next page)
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a-amanitin was added to inhibit host RNA polymerase, and
DENV vRNA synthesis monitored by incorporation of radioactive
32P-nucleotides into dsRNA duplexes (replicative form; RF) and
replication intermediates (RI) (Figure 3F). No radioactive species
were detected using uninfected cells (no DENV, Figure 3F, ii),
confirming their dependence on DENV RCs. As expected, the
NS5 inhibitor 20CMA blocked production of vRNA species
(Figure 3F, i). Of note, JG40 also caused a reduction in vRNA syn-
thesis (Figure 3F, i), and incubating the RCs with anti-Hsp70
antibodies blocked vRNA production in a concentration-depen-
dent manner (Figure 3F, ii). We conclude that the large 100 kDa
protein NS5 is a direct substrate of Hsp70, which is required for
both stabilizing NS5 and for continued NS5 activity after replica-
tion complexes assemble.
Hsp70 Associates with Capsid Protein and Promotes
Virus Production
A parallel analysis of the role of Hsp70 in capsid stability showed
MG132 did not fully restore the drop in capsid levels observed
with JG40 (Figure 4A). Since capsid associates with LDs (Samsa
et al., 2009) and vesicles, we considered lysosomal degradation
as an alternative degradation route. Despite the confounding
fact that the lysosome inhibitor concanamycin A (CM) reduces
overall DENV replication (not shown), co-incubation of JG40
with CM did partially restore capsid levels. We also observed
an additive effect of blocking both proteasomal and lysosomal
degradation (Figure 4A). JG40 also reduced levels of transfected
HA-capsid, circumventing the effect of these inhibitors on DENV
replication (Figure 4B). This reduction was partially abrogated by
independent treatment with MG132 and CM, and additively
blocked when both pathways were inhibited (Figure 4B). Thus,
JG40 induces capsid degradation via proteasomal and lyso-
somal routes.
Hsp70 also associated with capsid in co-immunoprecipitation
experiments (Figure 4C). Immunofluorescence analysis demon-
strated that, as reported (Balinsky et al., 2013; Samsa et al.,
2009), some of the capsid pool is directed to nucleoli, and in
the cytoplasm capsid associates with LDs and nearby vesicles,
forming puncta and ring-like structures distinct from sites con-
taining viral dsRNA (Figures 4D and S3). We therefore ques-
tioned whether Hsp70 is required for the assembly of viral parti-
cles. 20CMAor JG40were used to inhibit vRNA production 36 hpi
to compare the effect of the drugs on encapsidation of preexist-
ing vRNA (Figure 4E). Both inhibitors rapidly blocked vRNA syn-
thesis to a similar extent (Figure 4F), but had very different effects
on the accumulation of intracellular (Figure 4G) and extracellular(B) Hsp70 inhibition directly leads to proteasomal degradation of NS5. 293T cells
inhibitor MG132 for 36 hr and analyzed as in (A).
(C) Hsp70 physically associates with NS5. Strep-taggedHsp70 or aGFP control w
assessed by coimmunoprecipitation and immunoblot. Total: represents 20% of
(D) Rescue of NS5 levels by MG132 is not enough to restore DENV RNA replicatio
and levels of intracellular viral RNA and extracellular virus production measured
(A, B and C) Data are expressed as mean ± SD of three independent experimen
(E) In vitro RNA replication assay to test the effect of Hsp70 inhibition on activ
complexes were harvested from infected cells 48 hpi, and processed as describ
(F) Hsp70 is required for NS5 polymerase activity. [32P]-vRNA synthesized in vitro i
following addition of control or anti-Hsp70 antibody (ii). No vRNA is synthesized
independent experiments.
1114 Cell 163, 1108–1123, November 19, 2015 ª2015 Elsevier Inc.infectious virus (Figure 4H). Cells treated with 20CMA continue to
produce viral particles and secrete them into the medium for at
least 24 hr post-treatment. This suggests that by 36 hpi,
DENV-infected cells contain sufficient vRNA and proteins to
support the assembly of new virus particles. In contrast, JG40
treatment did reduce intracellular and extracellular virus accu-
mulation, suggesting Hsp70 plays an additional role in virion
biogenesis.
Selected J-Domain Proteins Are Required for DENV
Replication
How and why chaperones select their substrates in vivo is an
important and poorly understood question. Substrate selection
and stable binding to Hsp70 is thought to rely on DNAJ proteins
(Figure 5A), which in humans constitute the largest and most
diverse sub-group of chaperones. All DNAJs contain a J-domain
and additional domains confer distinct subcellular localization
and recruitment to specific complexes. Depending on their addi-
tional domains, DNAJs are classified into three types: type I, also
called DNAJA; Type II, or DNAJB; and Type III, or DNAJC (Kam-
pinga and Craig, 2010). The diversification of J-domain proteins
likely underlies the multifaceted regulation of Hsp70, however,
few examples exist of the division of labor among different
DnaJs.
To test if the distinct function of Hsp70 in the DENV life cycle is
driven by different DnaJ proteins, we conducted a comprehen-
sive screen using two or three shRNAs per J-domain protein in
human cells. Thirty-five of the KD cells were viable (Figure 5A,
S4A, S4B), and KD of DNAJs affecting DENV replication was
confirmed by qRT-PCR and immunoblot (Figures 5B and 5C).
DENV infection was significantly reduced upon depletion of eight
DNAJ proteins (Figure 5A, S4A), and enhanced upon depletion of
the known DENV restriction factor DnaJC14 (Yi et al., 2011).
Following electroporation of vRNA, four of the DNAJ proteins
no longer inhibited infectious virion production, suggesting
they participate in viral entry (Figure 5D-F). In contrast, five
DNAJs still inhibited DENV particle production (Figure 5D) and
vRNA synthesis (Figure 5E), which we independently confirmed
using enzymatically-produced esiRNAs (Figure S4C). The
distinction between DNAJs required in entry versus post-entry
steps was also confirmed by immunoblot for viral proteins
following vRNA electroporation (Figure 5F). The DNAJ proteins
required for DENV replication exhibit distinct domain structures
and subcellular localizations (Figure S4D) (Kampinga and Craig,
2010). Those involved in entry include DnaJC9, reportedly
nuclear localized, as well as the membrane-anchored DnaJC16transfected with HA-NS5 were treated with JG40 with or without proteasome
ere expressed together with HA-taggedNS5 in 293T cells, and their association
the IP input.
n and viral progeny production. NS5 degradation was blocked as in Figure 3A,
by qRT-PCR (left panel) and FFA (right panel), respectively.
ts. *p < 0.05. **p < 0.01
ity of preassembled, folded DENV replication complexes. Crude replication
ed.
n isolated replication complexes in the presence of NS5 or Hsp70 inhibitors (i) or
in extracts from uninfected cells. The data shown are representative of three
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Figure 4. Hsp70 Interacts with Capsid and Participates in Virion Production
(A and B) JG40 treatment leads to capsid degradation through proteasome- and autophagy-dependent pathways. (A) Huh7 cells were infected with DENV2 at
MOI 0.5. At 36 hpi, JG40 was added with or without proteasome inhibitor MG132 and/or lysosomal inhibitor CM for an additional 12 hr. Immunoblot analysis (left
panel) and quantification (right panel) show that the JG40-induced decrease in NS5 is rescued by MG132.
(B) 293T cells expressing HA-capsid were treated with JG40 with or without MG132 and/or CM for 36 hr and analyzed as in (A).
(C) Hsp70 physically associates with capsid. Strep-tagged Hsp70 or a GFP control were expressed together with HA-tagged capsid in 293T cells, and their
association assessed by coimmunoprecipitation and immunoblot.
(D) Hsp70 co-localizes with capsid in infected cells. Huh7 cells infected with DENV2were immunostained for Hsc70/Hsp70 (green), dsRNA (blue) and capsid (red)
48 hpi. Insets: ring-shaped structures formed by capsid due to its association with LD and vesicles. Scale bar, 10 mm
(E–H) Hsp70 is required for infectious viral particle production. (E) Scheme of drug-chase experiment comparing the effect of the NS5 inhibitor (20CMA) and the
Hsp70i JG40 on vRNA production and virion production. Huh7 cells infected with DENV2 at MOI 0.5 were treated at 36 hpi with 3 mM 20CMA or 3 mM JG40 and
levels of intracellular DENV RNA was measured by qRT-PCR (F); intra- and extracellular virion levels (G and H) were measured by FFA. Data are expressed as
mean ± SD of three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, *****p < 0.0005.
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and DnaJC18, which expose the J-domain into the cytosol.
Post-entry steps require DnaJA2, DnaJB6, DnaJB7, DnaJB11,
and DnaJC10. The cytosolic DnaJA2 significantly inhibited virus
production and vRNA synthesis, with only aminor impact on viral
proteins. The closely related DnaJA1 and DnaJA3 had little or no
effect on DENV replication, indicating that related isoforms can
have different substrate specificities. DnaJC10, a lumenal ER
chaperone (Kampinga and Craig, 2010), may participate in
folding ER-bound DENV proteins, or alternatively, host proteins
required for DENV replication. Membrane-anchored DnaJB11
is also ER localized (Kampinga and Craig, 2010). DnaJB6 exists
as two alternatively spliced isoforms: DnaJ6Ba is predominantly
nuclear and DnaJB6b is nuclear/cytoplasmic (Figure 5G, i). We
used shRNAs to selectively KD these splice-variants (Fig-
ure 5G, ii, S4E). DENV RNA replication, protein expression, and
virion production were all significantly reduced in DnaJB6b KD
cells but unaffected by DnaJB6a KD (Figures 5G, iii, S4E and
S4F). Thus, closely related DnaJs, and even splice-variants,
have divergent specificities and functions. We conclude that
the distributed action of DNAJ cofactors localized in distinct
cellular compartments orchestrates the many processes leading
to productive DENV infection.
Distinct Roles of DnaJB11 and DnaJB6b in DENV
Replication
We next focused on DnaJB11 and DnaJB6b, since their KD re-
sulted in strong post-entry effects. To distinguish between a
role in vRNA synthesis and viral particle assembly, we electropo-
rated an excess of vRNA into cells depleted of DnaJB6b or
DnaJB11. This incoming vRNA should provide enough template
for viral protein synthesis and biogenesis, reducing the require-
ment for vRNA synthesis (Figure 6A). Depletion of DnaJB6b
and DnaJB11 resulted in comparable reductions in vProtein
(Figure 6A, i) and vRNA (Figure 6A, ii). However, viral particle pro-
duction was virtually unaffected in DnaJB11-depleted cells, sug-
gesting that significant reductions in vRNA and vProtein levels
can have only modest effects on the output of viral particles. In
contrast, DnaJB6b depletion significantly reduced infectious
particle release (Figure 6A, iii). Therefore, DnaJB6b participates
in viral particle biogenesis, while DnaJB11 is not required if suf-
ficient vRNA and vProteins are present.
The observed reduction in viral infectivity upon DnaJB6 KD
could be due to reduced particle production or impaired particle
maturation. These possibilities make distinct predictions as to
how DnaJB6 KD affects the ratio of infectious versus total virions
(Figure S5A). To address this, we quantified vRNA genomes from
equivalent amounts of focus forming units (FFUs) from the super-Figure 5. A Subset of Human DNAJ Co-chaperones Is Required for the
(A) Screen for human DNAJ involvement in DENV replication. Forty-five human
Indicated DNAJ-KD cells were established as for Hsp70s in Figure 1, and infected
shRNA against luciferase.
(B and C) Validation of KD of different DNAJ isoforms by assessing mRNA levels
(D–F) Identification of DNAJs involved in post-entry stages of the DENV life cy
infectivity (D); intracellular viral RNA (E) and viral proteins (F) were measured afte
(G) Isoform DnaJB6b is required for DENV propagation. (i) Splicing creates DnaJB
for 36 hr. The levels of each variant transcript (ii) and extracellular viral produc
respectively. Data are representative of three independent experiments and exp
Cnatants of infected DnaJB6 KD or control cells. A reduction in
infectivity would predict that more viral particles, i.e., more
RNA genomes, will be required for the same number of FFU in
DnaJB6 KD cells. This was not the case (Figure S5A), confirming
that DnaJB6 is required for viral particle production itself.
Immunofluorescence analysis using confocal microscopy and
super-resolution stochastic optical reconstruction microscopy
(STORM) (Figures 6B, 6C, and S5B) indicated that DnaJB11 is
distributed throughout the cell, co-localizing with the ER, in unin-
fected cells. Upon infection, DnaJB11 was additionally enriched
in dsRNA-containing DENV replication complexes (Figures 6B,
6C, and S5B,). Immunoprecipitation of DnaJB11 followed by
RT-PCR analysis (Figure 6D) confirmed that both positive and
negative vRNA strands associate with DnaJB11, probably in
DENV replication complexes.
Since DnaJB6b is cytosolic and facilitates viral particle
biogenesis, we tested its association with capsid, the cytosolic
component of virions. DnaJB6b co-immunoprecipitated with
transfected HA-capsid (Figure 6E). In DENV-infected cells,
capsid was distributed throughout the cell and displayed a pre-
viously-described association with LDs (white arrow, shown in
inset) and other vesicular structures (Figure 6F) (Samsa et al.,
2009). While DnaJB6 localized to the cytosol and nucleus in un-
infected cells (Figures 6F and S5C), DnaJB6 co-localized with
capsid on vesicular structures and on the surface of LDs after
infection, and the proportion of nuclear DnaJB6 was slightly
reduced. These results suggest that DnaJB6 associates with
capsid to facilitate viral particle biogenesis. To test whether
DnaJB6b acts only through Hsp70, we employed two mutations
known to disrupt different aspects of DnaJB6b activity (Fig-
ure 6G, i). The Hsp70 recruitment ability of DNAJB6 was disrup-
ted by replacing its J-domain HPD motif with an AAA sequence.
DnaJB6 is mutated in inherited myofibrillar myopathy and limb-
girdle muscular dystrophy (Stein et al., 2014), and we also tested
the effect of a disease-linked DnaJB6b mutation on DENV repli-
cation (Figures 6G and S5D, F93L). In DnaJ-depleted cells, only
wild-type (WT) DnaJB6b fully restored viral production (Fig-
ure 6G, i–iii, and S5D). However, the HPD-AAA mutation, but
not the F93L mutation, had a modest effect in restoring vRNA
synthesis (Figure 6G, ii). Thus, the interaction of DnaJB6b with
Hsp70 is important to promote viral particle biogenesis, though
DnaJB6b may also possess intrinsic chaperone activity.
JG40 Inhibits the Replication of Divergent Flaviviruses
in Human Dendritic Cells
Primary humanmonocyte-derived dendritic cells (MDDCs) are an
established ex vivo model system for DENV (Figure 7A) (AguirreDENV Life Cycle
DNAJs were tested for effect on DENV by KD using three different shRNAs.
with DENV2 for 36 hr. Extracellular virus productionwasmeasured by FFA. Ctrl:
(B) and DNAJ protein (C).
cle. DENV vRNA was electroporated into DNAJ-KD cells. Extracellular viral
r 72 hr, by FFA, qRT-PCR and immunoblotting, respectively.
6 variants. KD cells were established for each variant, and infected with DENV2
tion (iii) were measured by qRT-PCR with variant-specific primers and FFA,
ressed as mean ± SD of triplicates. *p < 0.01.
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Figure 6. Spatial and Functional Diversity of DNAJs in DENV Propagation
(A) Introduction of excess DENVRNA by electroporation rescues DENV production in DnaJB11-KD, but not in DnaJB6-KD cells. Intracellular proteins (i), viral RNA
(ii), and extracellular viral infectivity (iii) were measured by immunoblot, qRT-PCR, and FFA, respectively, at 36 hpi. *p < 0.05
(legend continued on next page)
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et al., 2012; Rodriguez-Madoz et al., 2010), allowing us to
examine the therapeutic potential of Hsp70 inhibitors (Figures 7
and S6). JG40 dose-dependently inhibited DENV2 replication,
to undetectable levels at 5 mM (Figure 7C) but did not reduce
MDDC viability at these concentrations (Figure 7B). JG40 also
reduced vRNAaccumulation (FigureS6A). JG40’s higher potency
in primary MDDCs compared to Huh7 cells is interesting, since
transformed cells have disregulated chaperone activity, making
primary cells more responsive to chaperone inhibition (Trepel
et al., 2010). The therapeutic window for antiviral use of chap-
erone modulators is also greater in primary cells (Geller et al.,
2013; Geller et al., 2007). JG40 also inhibited DENV4, the most
divergent of the four DENV serotypes (Figures 7C and S6A). We
next examined the antiviral effects of JG40 on the flaviviruses
WNV (strain Kunjin; KUNV), YFV, and the TBEV model Langat
virus (LGTV). All three viruses were dose-dependently inhibited
by JG40 (Figures 7D, S6A, and S6B), and in all cases infectious
viruswasundetectablewith 5mMJG40 (Figure 7D). JG40 is there-
fore a broad spectrumantiviral active against distantly related fla-
viviruses, many of which have limited treatment options.
Effects of JG40 onCytokine andChemokine Induction in
DENV-Infected MDDCs
An ideal dengue therapy should attenuate the overproduction of
cytokines and chemokines associated with DHF/DSS as well as
viral replication. We therefore measured the effect of JG40 on
relevant cytokines and chemokines produced during DENV2 or
DENV4 infection in MDDCs (Figures 7E and S6C). The pro-in-
flammatory cytokines TNF-a, IL-6, and IL-1b induce fever and
may cause vascular permeability during DENV infection; the che-
mokine RANTES is involved in leukocyte recruitment, and type I
interferon (IFN) is involved in viral clearance but also contributes
to the ‘‘flu-like’’ symptoms of dengue disease (Charo and Ran-
sohoff, 2006; Rothman, 2011). As we showed previously,
DENV2 does not induce type I IFN, and transiently induces
pro-inflammatory cytokines and chemokines (Figure S6C)
(Aguirre et al., 2012; Rodriguez-Madoz et al., 2010). In contrast,
DENV4 induced higher levels of chemokines and pro-inflamma-
tory cytokines (Figures 7E and S6C), perhaps due to intrinsic viral
differences or due to higher replication levels (Figure 7C). JG40
dose-dependently reduced the induction of IFN-a, TNF-a,
RANTES, IL-1b, and IL-6 in DENV4-infected MDDCs (Figure 7E).
However, macrophage inflammatory protein 1b (MIP-1b),
involved in leukocyte recruitment (Charo and Ransohoff, 2006),
was unaffected (Figure S6C), indicating that JG40 does not
grossly alter the ability of DCs to induce and secrete proteins.(B and C) DnaJB11 relocalizes to DENV replication sites. Uninfected Huh7 cells or
dsRNA (green) and imaged using confocal microscopy (B) and super-resolution
(D) DnaJB11 physically associates with DENV vRNA. DENV-infected cell lysates
extracted and positive strand and negative strand detected by RT-PCR.
(E) DnaJB6b associates with capsid in the absence of infection. GFP-tagged DnaJ
and association measured by immunoprecipitation and immunoblot.
(F) DnaJB6 co-localizes with capsid in infected cells. Uninfected Huh7 cells or cell
(a marker of lipid droplets; red) and capsid (blue). Inset: magnification of capsid
(G) Wild-Type DnaJB6b, but not its mutants can rescue the reduced DENV propag
AAA mutation, disrupting Hsp70 binding, and disease associated F39L mutation
with DENV2 at MOI 0.5. At 36 hpi, intracellular viral RNA (ii) and extracellular virus
independent experiments and expressed as mean ± SD of triplicate. *p < 0.05, *
CIn principle, the effects of JG40 on cytokine and chemokine pro-
duction may stem from the inhibitor’s effects on viral replication,
and the resultant reduction in immunostimulatory pathogen-
associated molecular patterns (PAMPs). However, when we
directly stimulated MDDCs with the dsRNA mimic poly(I:C)
without viral infection, JG40 still reduced TNF-a and RANTES in-
duction, while IFN-awas unaffected (Figures 7F and S6D). Thus,
JG40 directly modulates the production of a subset of cytokines
independently of its effects on viral replication.
DISCUSSION
Due to their small genomes, RNA viruses rely on the host ma-
chinery to support their life cycle, providing a window into funda-
mental cellular processes. Here we examined the role of the
complex Hsp70 chaperone network, central to protein homeo-
stasis, in DENV replication. We find that distinct Hsp70 isoforms
and their DnaJ cofactors orchestrate the proteostatic control of
specific steps in the DENV life cycle. Distinct steps in DENV repli-
cation require different DNAJ Hsp70-cofactors localized to
distinct cellular compartments. Our data illustrate how a
non-specific chaperone like Hsp70 acquires functional and sub-
cellular specificity through the action of DNAJ cofactors. Further-
more, compounds targeting Hsp70 appear to be promising
antivirals, for several reasons. First, due to the dependence on
Hsp70 at various steps of the viral life cycle, DENV cannot
escape these drugs. Second, because these compounds allo-
sterically modulate Hsp70 rather than fully block its activity,
they exhibit negligible toxicity at concentrations that completely
block virus production. This favorable therapeutic window likely
arises from the chaperone-hyperdependence of the virus. Most
excitingly, these compounds are effective against different
DENV serotypes and diverse flaviviruses. Importantly, they also
decrease the virally-induced release of inflammatory cytokines
that contribute to severe dengue disease. The effectiveness of
antivirals is severely limited by the emergence and spread of
resistance (Lipsitch et al., 2007). However, so far no viral resis-
tance has been observed for three unrelated viruses treated
with inhibitors of two different chaperones, Hsp90 and Hsp70.
This unique property of targeting viral proteostasis may close a
gap in antiviral drug development.
Multiple DNAJs Facilitate Distinct Steps of the DENV
Replication Cycle
The Hsp70 network has become progressively diversified in evo-
lution (Powers and Balch, 2013). Our work on one simplecells infected with DENV2 for 48 hr were immunostained for DnaJB11 (red) and
microscopy by STORM (C). Scale bar, 10 mm
were subjected to immunoprecipitation with DnaJB11 antibodies. vRNA was
B6b or GFP were overexpressed together with HA-tagged capsid in 293T cells
s infected with DENV2 for 48 hr were immunostained for DnaJB6 (green), ADRP
containing cellular structure. Scale bar, 10 mm
ation in DnaJB6b KD cells. (i) DnaJB6b domain structure and position of HDP-
. DnaJB6b or its mutants were transfected into KD cells 48 hr prior to infection
production (iii) were measured as described. Data are representative of three
*p < 0.01.
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‘‘organism’’ that uses the protein folding machinery provides
insight into the division of labor and connectivity of the many
DNAJs and Hsp70s in human cells. It is striking how many
DNAJs are involved in viral replication. Nine DNAJs have strong
effects upon depletion, while others, such as DNAJC25 or
DNAJC13, have smaller but reproducible effects. As we
observed strong effects with single-gene depletions, there
must be limited redundancy among these DNAJ isoforms.
Some DNAJs, e.g., DNAJB11, were reorganized upon infection
(Figure 6) while others, e.g., DNAJA2, were not (data not shown).
Future studies should clarify whether DENV actively remodels
chaperone localization or whether the high levels of viral sub-
strates concentrate their binding factors.
Our data indicate a role for Hsp70 and a subset of DNAJs in
viral entry, and a direct role for Hsp70 and DNAJB11 in viral
RNA synthesis and for Hsp70 and DNAJB6 in virion production.
Hsp70 is not only required for folding and assembly but also for
function of the active replication complex. Interestingly, DNAJB6
is important in the regulation of protein aggregation diseases
(Hageman et al., 2010), suggesting this chaperone may function
to regulate protein assembly processes. While these DNAJs
have a direct role in viral proteostasis, at least some DNAJs
may participate in host processes required by DENV.
Therapeutic Potential of Hsp70 Inhibitors as Pan-
Flavivirus Antivirals
The Hsp70 inhibitor used here, JG40, caused over four logs
reduction in DENV2 and DENV4 replication in MDDCs, with
negligible toxicity to host cells. Since MDDCs closely model hu-
man physiology and disease, these reductions may more accu-
rately reflect the dependence of DENV on the cellular protein
folding machinery during human infection than cell lines. In addi-
tion, JG40 suppressed the production of proinflammatory cyto-
kines and chemokines, suggesting that Hsp70 inhibitors might
benefit patients both by directly inhibiting DENV replication,
and by reducing the production of cytokines contributing to se-
vere dengue disease. The comparison of JG40 with the specific
NS5 inhibitor 20CMA is informative for designing antiviral strate-
gies. While 20CMA is more specific and potent in inhibiting vRNA
production, the infected cell makes sufficient precursors to
continue new virus production long after inhibitor addition. In
contrast, JG40 simultaneously inhibits replication of viral RNA
and packaging of viral particles, increasing its effectiveness.Figure 7. JG40 Inhibits the Replication of DENV and Other Flaviviruses
DENV Infection
(A–C) JG40 potently inhibits different DENV serotypes at concentrations without
post-treatment. (B) Host toxicity of JG40 was determined by LDH release into th
infected with DENV2 or DENV4 at MOI 0.5 and subsequently treated with JG40 fo
UD, undetectable. Data are the mean of three independent donors, expressed a
(D) Broad Spectrum action of JG40 inhibiting the replication of diverse flaviviruses
treated with JG40 for 36 hr. The level of extracellular viral infectivity was measure
donors, expressed as mean ± SD.
(E) JG40 can suppress cytokine induction during DENV infection. Human MDDC
36 hr. Cytokine levels in the culture supernatant were measured by ELISA. *p < 0
(F) JG40 directly affects the production or secretion of a subset of cytokines. Huma
subsequently transfected with 5 mg/ml poly(I:C). Cytokine induction was measur
correction). One representative donor of three shown.
(G) Role of the Hsp70/DNAJ network at various steps in the DENV life cycle, hig
COne exciting finding is that JG40 is effective against a diverse
set of mosquito- and tick-borne flaviviruses that cause severe
human disease (Figures 7 and S6). Our experimental design in
primary human cells only measured post-entry effects, thus
these compounds might be even more effective in vivo as viral
entry would additionally be targeted. Future research should
further compare the chaperone requirements of different flavivi-
ruses at all stages of their life cycles.
Hsp70 inhibitorsmay represent a novel class of broadly-acting
antivirals to treat diverse flavivirus infections for which there are
no specific approved treatments. Considering their pan-flavivi-
rus specificity alongside the lack of observed resistance, such
compounds could become an important tool for reducing the
worldwide human disease burden caused by these diverse
viruses.
EXPERIMENTAL PROCEDURES
Infectious cDNA clone pD2/IC-30P-A of DENV2 (strain 16681) (from CDC
[Butrapet et al., 2000]) was used to in vitro transcribe vRNA that was electro-
porated into Huh7 cells to produce infectious DENV2. Kunjin virus (KUNV) and
Langat virus (LGTV) were kindly provided by Dr. Jean Lim (Icahn School of
Medicine at Mount Sinai, NY, USA). DENV and yellow fever virus (YFV) stocks
were prepared in Huh7 and C6/36 cells; KUNV and LGTV stocks were pre-
pared on Vero cells. Virus titrations were carried out using the methylcellulose
overlay method as described in Supplemental Experimental Procedures.
Cells were maintained at 37C (Huh7) or 32C (C6/36). MDDCs were gener-
ated from healthy human blood donors (New York Blood Center, NY, USA) as
described (Rodriguez-Madoz et al., 2010). qRT-PCR quantification of purified
RNA was performed using primers specified in Table S1. Transcripts were
normalized to GAPDH or Rps11 mRNA (human) or 18S rRNA (mosquito). Viral
genome equivalents were quantified using +ssRNA virus-specific standards.
Each experiment was independently performed at least three times and
each time was performed in triplicate.
Extracellular secreted cytokines were quantified using a customized multi-
plex ELISA (Millipore, Billerica, MA, USA) as per manufacturer’s instructions.
Plasmid transfections, immunoprecipitations, immunoblots, isolation of
DENV replication complexes, and in vitro DENV replication assay and other
biochemical analyses were performed as described in the Supplemental
Experimental Procedures. For immunofluorescence, cells cultured on glass
slides were incubated with the relevant primary and secondary antibodies
and imaged by confocal microscope and stochastic reconstruction micro-
scopy (STORM) as described in Supplemental Experimental Procedures.
Statistical significance was determined using two-tailed Student’s t test
analysis for samples of equal variance, with sequentially rejective Bonferroni
correction where appropriate. Significance levels are as stated in the figure
legends.in Primary Human MDDCs and Modulates Cytokine Induction during
toxicity to the host cell. (A) Effects of JG40 in primary human MDDCs at 36 hr
e culture supernatant. Differences are not statistically significant. (C) MDDCs
r 36 hr. The level of extracellular viral infectivity was measured by plaque assay.
s mean ± SD.
. MDDCs were infected with KUNV, YFV or LGTV at MOI 0.5 and subsequently
d by plaque assay. UD, undetectable. Data are the mean of three independent
s were infected with DENV4 (MOI 0.5) and subsequently treated with JG40 for
.05, **p < 0.01. One representative donor of three shown.
nMDDCswere treatedwith increasing amounts (0, 1, 5, or 10 mM) of JG40, and
ed by ELISA. *p < 0.05, **p < 0.01 (one-tailed Student’s t test with Bonferroni
hlighting the therapeutic potential of Hsp70 inhibitors (see text for details).
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